Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT)

American Journal of Cardiology

Volumn 89, Issue 12, 2002, Pages 1414-1416

  Mancini, G B John ^a   Miller, Michael E ^a   Evans, Gregory W ^a   Byington, Robert ^a   Furberg, Curt D ^a   Pitt, Bertram ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE;

ANGIOGRAPHY; ARTERY DIAMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 0037097476     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02357-3     Document Type: Article

References (7)

1. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events
2. Retardation of angiographic progression of coronary artery disease by nifedipine
3. A controlled clinical trial to assess the effect of a calcium antagonist on the progression of coronary atherosclerosis
4. Compensatory enlargement of human atherosclerotic conronary arteries
5. Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries
6. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular effects of Norvasc Trial (PREVENT)
7. Random-effects models for longitudinal data